{"url_path":"/sec/alxo/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1810182/0001193125-26-213399-index.html","accession_number":"0001193125-26-213399","cik":"0001810182","ticker":"ALXO","issuer_name":"ALX ONCOLOGY HOLDINGS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1810182/0001193125-26-213399-index.html","primary_entity_key":"0001810182","primary_entity_name":"ALX ONCOLOGY HOLDINGS INC"},"word_count":114,"has_tables":true,"body_markdown":"Item 2. Unregistered Sales of Equity Securities and Use of Proceeds\n\nUse of Proceeds from Initial Public Offering of Common Stock\n\nThere has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC on July 17, 2020 pursuant to Rule 424(b)(4). We invested the funds received in accordance with our investment policy. None of such payments were direct or indirect payments to any of our directors or officers (or their associates), to persons owning ten percent or more of our common stock or to any other affiliates.\n\nUnregistered Sales of Equity Securities\n\nNone.\n\nIssuer Purchases of Equity Securities\n\nNone."}